Raskob GE, et al. - Researchers intended to discern the role of treatment with direct oral anticoagulant agents cancer-associated venous thromboembolism. With regard to the composite outcome of recurrent venous thromboembolism or major bleeding, oral edoxaban was discovered to be noninferior to subcutaneous dalteparin. The findings also unveiled lower rate of recurrent venous thromboembolism. However, a higher rate of major bleeding was brought to light with edoxaban than with dalteparin.